BAT Science - Clinical study shows that switching to glo reduces smokers’ exposure to harmful chemicals

Quick Navigation

Jump to content
News and Conferences

Clinical study shows that switching to glo reduces smokers’ exposure to harmful chemicals

18 June 2018

• glo is a tobacco heating product designed to heat rather than burn tobacco.

• Tests show that glo vapour has around 90-95% less harmful chemicals than smoke*

• Clinical studies by scientists at British American Tobacco indicate that when smokers switched completely from conventional cigarettes to glo, their exposure to many harmful chemicals found in cigarette smoke was significantly reduced**.

• In some cases, the reductions were the same as those in smokers who quit altogether.

• These data suggest the potential for glo to be a reduced-risk product***.

SOUTHAMPTON, UK; and WARSAW, POLAND, 15 JUNE 2018:  A study by scientists at British American Tobacco has shown then when smokers switch completely to glo, their exposure to harmful smoke chemicals is substantially reduced, in some cases to levels comparable to those seen in smokers who quit smoking completely**.

It is widely accepted that most of the harm associated with tobacco is caused by inhaling harmful chemicals in the smoke produced when it is burned.  That is why at British American Tobacco, we are dedicated to the development and sale of a range of potentially reduced-risk products that provide the enjoyment of smoking without burning tobacco.  This portifolio includes our tobacco heating product, glo, which previous studies have shown to contain around 90-95% less harmful chemicals than cigarette smoke*.

“The results of this clinical study, which involved 180 people, show that the reduction in the level of harmful chemicals in glo vapour translates to a reduction in exposure when smokers switch to using glo,’ according to Dr James Murphy, Head of Reduced Risk Substantiation at British American Tobacco.  These results are very encouraging,” explains Murphy. “The next step will be to determine whether this reduction in exposure translates to a reduction in biological effect, and in turn a reduction in adverse health effects for those smokers who switch completely to glo. 

The results are published in the journal Nicotine & Tobacco Research and are presented today at the Global Forum on Nicotine in Warsaw, Poland.

About this Clinical Study

This study was conducted in Japan over a seven-day period in a clinic. One hundred and eighty people participated in the study, all of whom were smokers for at least three years prior to enrolment. 

For the first two days, study participants continued to smoke as normal and their urine was collected to measure selected biomarkers of exposure. Blood and breath were also collected for analysis.

Over the next five to six days, participants were randomly allocated to either continue smoking, switch to using glo or quit smoking. Urine, blood and breath samples were again collected for analysis.

Exposure to harmful chemicals in smoke was determined by measuring the levels of certain chemicals in the urine.  These could be the chemicals themselves or their metabolites – which is what the body breaks it down into - called biomarkers of exposure.  Chemicals measured included some of those identified by the World Health Organisation as being of concern in cigarette smoke.

The results show that the concentration of certain chemicals in the urine was reduced in smokers who switched to glo.  In some cases, these reductions were the same as those in smokers who quit.  This suggests that smokers who switched to glo were exposed to less harmful chemicals. In some cases, their exposure was the same as smokers who quit altogether***.

To read the full paper published in Nicotine & Tobacco Research, click here Opens new window.

British American Tobacco’s Commitment to NGPs

British American Tobacco have invested more than US$2.5 billion over the last six years in developing and commercialising a world-leading portfolio of products in the Next Generation Products (NGPs) category.  British American Tobacco currently has NGPs in 16 markets with plans to double the amount of markets we’re in by the end of 2018.  BAT has a bold ambition to realise revenue of more than £5bn from NGPs by 2022.

ENDS
 

 
 
 
 
Next Article

News Releases 2017

   
max
large
medium
small
mobile